The 10-year Treasury yield on Wednesday surged the most in three years to trade above 2%, a level not seen since January, on expectations Donald Trump will significantly boost fiscal spending, adding to the country��s debt burden.
��Right now, it��s a fear trade,�� said Kevin Giddis, head of fixed-income capital markets at Raymond James. ��While it is very early and most are trying to understand the forward thinking, the general perception is that a Donald Trump presidency will take us further into debt and ultimately be inflationary, affecting the values of all debt, including Treasurys.��
Hot Value Stocks To Watch For 2017: Netlist, Inc.(NLST)
Advisors' Opinion:- [By Jim Robertson]
On Friday, our Elite Opportunity Pro�newsletter suggested small cap data/memory solutions stocks�Netlist, Inc (NASDAQ: NLST) as a long/bullish position for our short term portfolio:
Hot Value Stocks To Watch For 2017: Teva Pharmaceutical Industries Limited(TEVA)
Advisors' Opinion:- [By Paul Ausick]
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) dropped about 1.1% on Friday to post a new 52-week low of $45.76 against a 52-week high of $66.55. Volume of nearly 11 million was around double the daily average of 6 million shares traded. The stock closed at $46.29 on Thursday night. The drug maker had no specific news Friday.
- [By Ben Levisohn]
Allergan�mgmt is considering a range of capital deployment alternatives. The focus on the conference call was around future capital deployment. Mgmt remains highly optimistic the Teva Pharmaceutical Industries (TEVA) deal will close by late 1H��16, noting both mgmt teams are ��absolutely aligned�� on getting the deal done and the deal proceeds will be after-tax net cash/equity of ~$36B. Mgmt��s is currently looking at a broad range of capital deployment options including debt pay down, share buyback and M&A. In our view,�Allergan will likely put the TEVA proceeds to work through a mix of these options. The company has ~$6B of debt maturing in the next 2-years which it could look to repay and there are a few small to mid-size M&A targets that�Allergan could look to acquire. In terms of timing, mgmt commented that it ��would not hesitate for the right opportunity�� which suggests to us smaller bolt-on transactions aren��t gated by the completion of TEVA deal.
- [By Ben Levisohn]
Johnson & Johnson (JNJ) now has a market cap of $308 billion dollars, just a smidgen less than that of Gilead Sciences (GILD), Biogen (BIIB), Mylan (MYL), Celgene (CELG) and Teva Pharmaceutical Industries (TEVA) combined. It’s time to sell, says Standpoint Research’s Ronnie Moas:
- [By Kanak Kanti, De]
Last week, Israel-based Teva Pharmaceuticals' (NYSE: TEVA ) generic product portfolio received a major boost after the Food and Drug Administration approved the company's generic version of Xeloda, a cancer drug. Roche's (NASDAQOTH: RHHBY ) Xeloda is an orally administered chemotherapy treatment for colorectal and breast cancers that have metastasized. Given the fact that Xeloda generated $1.6 billion in sales for Roche in 2012, Teva's generic version has significant potential.
Hot Value Stocks To Watch For 2017: BioPharmX Corporation(BPMX)
Advisors' Opinion:- [By Lisa Levin]
Shares of BioPharmX Corp (NYSE: BPMX) were down 31 percent to $1.02 after the company announced the pricing of 3.6 million share common stock.
Puma Biotechnology Inc (NYSE: PBYI) was down, falling around 22 percent to $27.53 after the company issued an update to the timeline for the filing of a new drug application. Puma Biotechnology will submit the NDA for neratinib in mid-2016. According to a press release, the decision was based on the company's recent meetings with the U.S. Food and Drug Administration.
